title: Long-chain n-3 PUFA against breast and prostate cancer: Which are the appropriate doses for intervention studies in animals and humans?
abstract: The potential antineoplastic effect of the long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) remains a highly controversial issue. Numerous animal studies have supported the anticancer role of these dietary fatty acids, whereas conflicting results have been obtained in population studies, and only a few intervention human trials have been so far performed. In view of the possibility that the anticancer effects may be maximally observed within a defined range of EPA and DHA doses, herein we critically review the results and doses used in both animal studies and human clinical trials focusing on the possible n-3 PUFA protective effects against breast and prostate cancer. Our main aim is to identify the EPA and/or DHA ranges of doses needed to obtain clear anticancer effects. This may be of great help in designing future animal studies, and also in understanding the most appropriate dose for further human intervention studies. Moreover, since the healthy effects of these fatty acids have been strictly related to their increased incorporation in plasma and tissue lipids, we also examine and discuss the incorporation changes following the administration of the effective anticancer EPA and/or DHA doses in animals and humans.
authors.affiliation: a Institute of General Pathology, Università Cattolica S. Cuore , Rome , Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Fasano
authors.affiliation: a Institute of General Pathology, Università Cattolica S. Cuore , Rome , Italy.
authors.forename: Simona
authors.initials: S
authors.lastname: Serini
authors.affiliation: a Institute of General Pathology, Università Cattolica S. Cuore , Rome , Italy.
authors.forename: Achille
authors.initials: A
authors.lastname: Cittadini
authors.affiliation: a Institute of General Pathology, Università Cattolica S. Cuore , Rome , Italy.
authors.forename: Gabriella
authors.initials: G
authors.lastname: Calviello
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D004281:Docosahexaenoic Acids / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid
keywords: Bioavailability; breast cancer; dose; incorporation; n-3 PUFA; prostate cancer